Ibuprofen 600 mg Immediate Release/Extended Release Caplet

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Sep 24, 2012 → Jun 3, 2013

NCT ID

NCT01789606

About Ibuprofen 600 mg Immediate Release/Extended Release Caplet

Ibuprofen 600 mg Immediate Release/Extended Release Caplet is a phase 3 stage product being developed by Pfizer for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT01789606. Target conditions include Analgesia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03722238	Phase 3	Terminated	Dec 27, 2018	Oct 28, 2019	Pain
NCT01789606	Phase 3	Completed	Sep 24, 2012	Jun 3, 2013	Analgesia

Competing Products

20 competing products in Analgesia

See all competitors

Product	Company	Stage	Hype Score
Acetaminophen	Johnson & Johnson	Phase 2	52
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	52
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation	Jiangsu Hengrui Medicine	Phase 1	33
Bupivacaine Liposome Injection	Jiangsu Hengrui Medicine	Approved	85
Paracetamol injection + Normal Saline injection + Morhpine PCA	Jiangsu Hengrui Medicine	Phase 2/3	65
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride Injection	Jiangsu Hengrui Medicine	Phase 2	52
Org 28611 + morphine sulfate + Placebo	Merck	Phase 2	52
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride	Pfizer	Phase 1	32
HSK21542 Injection + Tramadol hydrochloride + placebo	Haisco Pharmaceutical Group	Phase 3	74
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + Placebo	Haisco Pharmaceutical Group	Phase 2	49
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + Placebo	Haisco Pharmaceutical Group	Phase 2	49
HSK21542 + Placebo	Haisco Pharmaceutical Group	Phase 3	74
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011	Heron Therapeutics	Phase 3	69
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + Acetaminophen	Heron Therapeutics	Approved	77
HTX-011 + HTX-011 + Ibuprofen + Acetaminophen	Heron Therapeutics	Phase 2	44
Bupivacaine HCl	Heron Therapeutics	Approved	77
HTX-011 + Placebo	Heron Therapeutics	Phase 2	44
HTX-011 + Ibuprofen + Acetaminophen	Heron Therapeutics	Phase 3	69
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusion	Heron Therapeutics	Approved	77
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011	Heron Therapeutics	Phase 2	44

Other Products from Pfizer